# A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

> **NCT04959981** · PHASE1 · COMPLETED · sponsor: **Erasca, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Advanced Non-squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** ERAS-007
- **DRUG:** ERAS-601
- **DRUG:** Osimertinib
- **DRUG:** Sotorasib

## Key facts

- **NCT ID:** NCT04959981
- **Lead sponsor:** Erasca, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-02
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-04-27
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04959981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04959981, "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04959981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*